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http:WHAT THIS PAPER ADDS
Anemia, a common condition in patients hospitalized for peripheral arterial disease, is independently associated
with poor limb and general outcome. The risk of major amputation and death increases substantially at low
levels of hemoglobin. Whether a timely and adequate treatment of anemia in these patients may improve their
limbs and general outcome should be a new ﬁeld of investigation.Objectives: Anemia is associated with poorer outcome in coronary artery disease (CAD) and heart failure (HF),
but data on patients with peripheral artery disease (PAD) are scarce, especially regarding the local (limb)
prognosis. It was hypothesized that anemia is associated with poorer prognosis in patients hospitalized for PAD,
and this relationship would be proportional to the severity of the anemia.
Design: Prospective cohort study.
Materials: The Cohorte des Patients Artéritiques (COPART) is a multicenter registry of patients hospitalized for
PAD in three university hospitals in southwestern France.
Methods: Clinical and biological data were collected at entry. Patients were followed up to 1 year. Anemia was
deﬁned by Hb < 8.2 mmol/L in men and <7.6 mmol/L in women. The primary outcome was 1-year survival free
from major amputation. The secondary outcome was 1-year major amputation.
Results: Data of 925 consecutive patients (70.7  12.8 years, 29.2% females) were analyzed. Patients were
hospitalized either for revascularization or medical therapy, with Rutherford categories 3 (25%), 4 (9.1%), 5 or 6
(55.1%) as well as acute limb ischemia (10.8%). Anemia was present in 471 patients (50.9%). These patients were
signiﬁcantly older, with higher rates of hypertension, diabetes, clinical CAD, HF, chronic kidney disease, and
cancer, and with lower rates of smoking and dyslipidemia than their counterparts (p < .05 for all). In multivariate
models, anemia was signiﬁcantly and independently associated (p < 0.001) with death and amputation (HR 1.44;
95% CI 1.15e1.80) with similar ﬁndings for secondary outcomes. A lower level of hemoglobin is associated with a
higher risk of mortality and amputation (HR 1.20; 95% CI 1.09e1.32).
Conclusion: Anemia and its severity are independent predictors of mortality and limb loss in patients hospitalized
for PAD.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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//dx.doi.org/10.1016/j.ejvs.2014.04.005including oxygen carrying capacity, inﬂammatory processes,
oxidative stress, and blood viscosity. Anemia is a common
condition among older adults, and more recently it has
been shown that this condition is associated with increased
mortality,1e4 disability, and poorer physical performance1
regardless its underlying cause. In patients with coronary
artery disease (CAD), anemia is an independent predictor of
short- and long-term mortality.5e7 At the other end of the
hemoglobin range, patients with an acute coronary syn-
drome or congestive heart failure with elevated hemoglobin
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reverse J-shaped relationship.1e4,7e9 The relationship be-
tween hemoglobin levels and outcome in PAD patients is
unknown, and whether anemia predicts adverse outcomes
independent of other prognostic factors, such as kidney
disease or other confounders, has not been entirely
assessed. Beyond the cardiovascular events and survival,
the association between hemoglobin and limb loss has not
been assessed. It was hypothesized that anemia is common
in patients with severe PAD and is associated with an
increased risk of morbidity and mortality in PAD patients,
and also that the limb survival in these patients is affected
by the level of hemoglobin. The COPART registry, a multi-
center study assessing the prognosis of patients hospitalized
for PAD provides a unique opportunity to assess these
hypotheses.METHODS
Study design
The COPART registry (COhorte des Patients ARTériopathes)
is a multicenter prospective cohort of consecutive patients
hospitalized for the ﬁrst time for PAD in three tertiary care
academic centers in southwestern France. The registry has
been presented in detail elsewhere.10 Brieﬂy, the patients
were hospitalized either for severe claudication requiring
revascularization, or chronic limb ischemia, or acute limb
ischemia related to atherosclerotic lesions. These patients
were consecutively recruited initially in the department of
vascular medicine of Rangueil Hospital, University of Tou-
louse, from June 2004. The registry has been extended to
the departments of vascular medicine in Bordeaux (Saint-
André Hospital, Bordeaux University) and Limoges
(Dupuytren University Hospital) since October 2006. The
current study is limited to those hospitalized upto January
1, 2010. In each center, patients were managed according to
usual practice without any speciﬁc change in the manage-
ment strategy of participants.
The study was approved by the institutional review board
of Toulouse University. Written informed consent was ob-
tained from all participating subjects according to the
Declaration of Helsinki.Study population
A computerized case-record form was completed for each
patient. Initial characteristics and the clinical and thera-
peutic data on admission, during hospitalization and at
discharge were collected. The data collected at admission
included age, gender, CVD risk factors, and PAD clinical
presentation according to the Rutherford classiﬁcation.11 A
peripheral blood sample was obtained from each patient
after overnight fasting. The cardiovascular risk factors were
deﬁned as follows: diabetes was deﬁned by documented
medical history, the use of oral antidiabetic agents or insulin
or fasting plasma glucose levels of at least 1.26 g/L; dysli-
pidemia was deﬁned by a documented medical history, use
of lipid-lowering agents for this purpose or fasting low-density lipoprotein (LDL) cholesterol greater than 240 mg/
dL; hypertension was deﬁned by documented medical his-
tory and use of antihypertensive drugs for this purpose, or
systolic blood pressure (SBP) of at least 140 mmHg or dia-
stolic blood pressure (DBP) of at least 90 mmHg at admis-
sion determined by the average of the ﬁrst two
measurements. Patients were considered as current
smokers if they were smoking at least one cigarette per day.
Patients were considered as past-smokers if they had
stopped smoking at least 1 year prior to inclusion in the
study. The following cardiovascular diseases were noted,
according to the documented medical history: CAD, heart
failure, atrial ﬁbrillation, presence of a pacemaker at
admission, and cerebrovascular disease (CBVD) including
ischemic or hemorrhagic stroke as well as transient ischemic
attack. Chronic kidney disease (CKD) was deﬁned as previ-
ous history or noted according to the estimated glomerular
ﬁltration rate (eGFR) according to the Modiﬁcation of Diet
in Renal Disease (MDRD) Study equation, and chronic kid-
ney disease was deﬁned when eGFR was less than
60 mL min1 1.73 m2. The hemoglobin (Hb) value was
measured on admission. Anemia was diagnosed when the
Hb level was less than 8.2 mmol/L in men, and less than
7.6 mmol/L in women, according to the WHO deﬁnition.12Follow-up
The follow-up sequential procedure consisted of reviewing
patient ﬁles for outpatient visits, consulting mortality data
at registrar’s ofﬁces, mailing to the family physicians and/or
cardiologists/angiologists, and, ﬁnally, contacting the pa-
tients themselves, if necessary.
Outcome variables. The primary outcome was combined 1-
year mortality and major amputation. The secondary
outcome was 1-year major amputation.11Statistical analyses
For quantitative variables, means and standard deviations
(SDs; or median for non-parametric data) are presented.
Discrete variables are presented as numbers and percent-
ages. Comparisons were made with chi-square test (or
Fisher’s exact tests, when appropriate) for discrete vari-
ables, and by KruskaleWallis test for continuous variables.
In-hospital and 1-year survival rates after the index hospi-
talization were presented as percentages and comparisons
were made by chi-square tests. KaplaneMeier survival
curves were used with log-rank test to compare the 1-year
mortality in different subgroups. After the “restricted cubic
splines” analysis, the Cox regression model was used to
assess the survival according to the degree of anemia.1416
Several analyses were performed. First, age, gender Ruth-
erford classiﬁcation of PAD and center were used (Model 1).
Second, analyses were performed to explore the impact of
potential cardiovascular risk factors as tobacco, hyperten-
sion, diabetes, and dyslipidemia (Model 2). Third, to ensure
that participants with prevalent CVD were not responsible
for the study results, an analysis was conducted to examine
204 I. Desormais et al.the anemia-PAD interaction in participants with and
without a baseline history of CVD, medication, bronchitis,
cancer, and GFR less than 60 mL/min (Model 3).
With the resultant hazard ratios (HR), a HR of at least 1
indicates a shorter time to event occurrence and a HR less
than 1 indicates a longer time-to-event occurrence.RESULTS
Among the 1039 patients in the database at the time of this
analysis, 96 patients were excluded because of incomplete
data, and 18 patients were lost during follow-up. Mean age
of excluded patients was 71  12.9 years (men 75%) and
the prevalence of the associated cardiovascular risk factors
(hypertension 75%, smoking 23.4%, dyslipidemia 50%, and
diabetes 43.7%) were comparable with those of the
included subjects.
The ﬁnal cohort consisted of 925 patients with PAD. Pa-
tients were predominantly men (N ¼ 655, 70.8%) with a
mean age 70.7  12.8 years. Table 1 shows the general
characteristics of the study population. The prevalence of
anemia in our population was 50.9% (471 subjects) with a
majority of men 71.1% (335 subjects). The prevalenceTable 1. Baseline characteristics of patients presenting to hospital wit
Characteristics Study population (n ¼ 925)
N or mean (%)
(SD)
Age 70.7 (12.8)
Male gender 655 (70.8)
Medical history
Arial ﬁbrillation (n ¼ 918) 191 (20.8)
Coronary artery disease 354 (38.3)
Stroke 140 (15.1)
Atherosclerotic disease
(other than PAD)
426 (46.0)
Heart failure (n ¼ 918) 121 (13.2)
Cancer (n ¼ 898) 94 (10.5)
Asthma, bronchitis 127 (13.7)
Cardiovascular risk factors
Hypertension 714 (77.2)
Smoking (n ¼ 907) 222 (24.5)
Dyslipidemia 487 (52.6)
Type-2 diabetes 403 (43.6)
Baseline data
Heart rate (bpm) (n ¼ 882) 76.4 (14.7)
Hemoglobin; mmol/L 7.9 (1.3)
GFR; mL/min/1.73 m2 (n ¼ 922) 67.2 (34.1)
Rutherford categories
3 231 (25.0)
4 84 (9.1)
5 and 6 510 (55.1)
ALI 100 (10.8)
Medical treatment
Anti-platelet drugs (n ¼ 924) 690 (74.7)
Beta-blockers (n ¼ 924) 251 (27.2)
Renin-angiotensin system
inhibitors (n ¼ 924)
500 (54.1)
Statins (n ¼ 924) 598 (64.7)increased with age. Patients with and without anemia are
compared in Table 1. Anemia was less frequent among
smokers, but more frequent in diabetic and hypertensive
patients.
During follow-up, 246 patients (26.6%) experienced a
major amputation. During the same period 228 (24.6%)
died, 14 (1.5%) suffered a myocardial infarction, and 19
(2.0%) had a cerebrovascular event (stroke or TIA).
Overall, almost half of the participants (44.7%) had a
major event such as death, myocardial infarction, stroke, or
major amputation.
Outcomes of the excluded patients were compared with
the included subjects. No signiﬁcantly statistical difference
was found for both outcomes (37 of 96 subjects died or had
major amputation, p ¼ .1336, and 17 had major amputa-
tion, p ¼ .4596).
The occurrence of primary and secondary outcomes ac-
cording to the anemia status are presented in Fig. 1. Pa-
tients with anemia at entry experienced signiﬁcantly
(p < .0001) higher rates of death and amputation during
the following year. Similar results were found for the sec-
ondary outcome (major amputation). In the multivariate
analysis, anemia was signiﬁcantly associated withh PAD (n ¼ 925).
No anemia (n ¼ 454) Anemia (n ¼ 471) p
N or mean (%)
(SD)
N or mean (%)
(SD)
67.7 (13.5) 73.5 (11.3) <.0001
320 (70.5) 335 (71.1) .8303
82 (18.1) 109 (23.1) .0463
159 (35.0) 195 (41.4) .0460
66 (14.5) 74 (15.7) .6185
193 (42.5) 233 (49.5) .0338
42 (9.3) 79 (16.8) .0005
30 (6.6) 64 (13.5) .0004
62 (13.6) 65 (13.8) .9493
325 (71.6) 389 (82.6) <.0001
154 (33.9) 68 (14.4) <.0001
268 (59.0) 219 (46.0) .0001
146 (32.1) 257 (54.6) <.0001
74.8 (13.7) 78.0 (15.5) .0017
8.9 (0.7) 6.9 (0.8) <.0001
72.0 (28.9) 62.8 (37.9) <.0001
181 (39.9) 50 (10.6) <.0001
43 (9.5) 41 (8.7)
168 (37.0) 342 (72.6)
62 (13.7) 38 (8.1)
358 (78.8) 332 (70.5) .0041
132 (29.1) 119 (25.3) .1995
260 (57.3) 240 (50.9) .0585
330 (72.7) 268 (56.9) <.0001
Anemia
Anemia
p<0.0001
No-anemia
No-anemia
P<0.0001
A
B
0 mth 4 mths 8 mths 12 mths 14 mths
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471 291 234 144 46
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Figure 1. The 1-year prognosis of patients hospitalized for PAD
according to the anemia status: the COPART registry (2004e2010):
(A) Major amputation-free survival, (B) Major amputation.
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justments to several confounders (Table 2). Higher rates of
amputation were also found to be proportional to the low
hemoglobin level.
Using Cox proportional hazard models, adjusted for age,
gender, and clinical characteristics, anemia was associated
with increased risk of 1-year amputation-free survival
compared with non-anemic patients as presented in
Table 2. Additionally, hemoglobin level was signiﬁcantly and
proportionally associated with 1-year major amputation
(Table 3).
Similar results, enhancing the inﬂuence of the hemoglo-
bin level on both outcomes (death and amputation and
major amputation), were found after exclusion of CI and ALI
subjects (Table 4).DISCUSSION
This study conﬁrms our hypothesis that anemia is a strong
and independent predictor of death and limb loss inTable 2. Association of anemiaa with different outcomes of the study
Model 1b
HR 95% CI
Death and amputation 1.58 1.28e1.96
Amputation 1.56 1.18e2.06
a Compared with no-anemia group (HR ¼ 1).
b Adjusted for center, age, gender and PAD clinical presentation (Ruth
c Model 1 þ smoking, hypertension, dyslipidemia, diabetes, CKD.
d Model 2 þ history of CAD, stroke, heart failure, bronchitis, cancer, cpatients hospitalized for PAD. The association was gradual,
with increasing risk of amputation with increasing severity
of anemia. Similar results were found for the secondary
outcome (major amputation).
The prevalence of anemia in patients with PAD was high
in this series, and in line with that reported in a series of
patients with chronic limb ischemia.17 These data conﬁrm
the importance of the measurement of hemoglobin levels
as proposed by the TASC-2 guidelines.18 The presence of
anemia in this case would lead to a systematic work-up to
ﬁnd out its cause to determine adequate treatment.
Several pathways can be used to explain these ﬁndings.
Chronic anemia may increase left ventricular preload,
reduce afterload, and cause increased cardiac output.19 In
the long term, this may result in maladaptive left ventricular
hypertrophy (LVH), which in turn is a well-recognized risk
factor for CVD outcomes and all-cause mortality.20e22 The
presence of anemia may also exacerbate cardiac ischemia as
a result of decreased supply or increased demand for oxy-
gen, especially in the case of underlying coronary disease or
those with LVH. Several studies in various populations have
evaluated the importance of anemia as a risk factor for
adverse outcomes. In patients with heart failure, anemia is
associated with an increased risk of hospitalization and all-
cause mortality. Similarly, in patients with CKD, anemia has
been shown to be a risk factor for adverse outcomes.23e26
Data are scarce concerning the exact relationship between
the degree of preoperative anemia and long-term risk of
cardiac morbidity and mortality in vascular surgery patients.
Previous studies have shown that preoperative anemia in-
creases the risk of death or major cardiovascular events27,28
especially in patients with a history of cardiovascular dis-
ease.29 Recently, Dunkelgrun et al.30 studied the contribu-
tion of anemia to the risk of perioperative and long-term
cardiac outcome in 1211 patients undergoing elective non-
cardiac open vascular surgery. They found that the presence
and severity of anemia are signiﬁcant predictors of 30-day
and 5-year cardiac events, regardless of underlying heart
failure or renal dysfunction. Goei et al.31 conﬁrmed that
anemia is independently associated with an increased risk
for postoperative cardiac events in patients undergoing
vascular surgery. Nevertheless, available data do not pro-
vide any information regarding the degree of preoperative
and perioperative anemia, and the risk of amputation in
vascular surgery patients.
Although this study conﬁrms the importance of anemia
for the general prognosis in patients with severe PAD, to(multivariate analysis).
Model 2c Model 3d
HR 95% CI HR 95% CI
1.51 1.21e1.87 1.44 1.15e1.80
1.49 1.12e1.98 1.47 1.10e1.96
erford categories).
urrent treatment.
Table 3. Association between the reduction in hemoglobin (mmol/L) and different outcomes of the study (multivariate analysis).
Model 1a Model 2b Model 3c
HR 95% CI HR 95% CI HR 95% CI
Death and amputation
1.24 1.13e1.35 1.21 1.10e1.33 1.20 1.09e1.32
Amputation
1.22 1.09e1.36 1.21 1.07e1.36 1.20 1.07e1.36
a Adjusted for age, gender, and PAD clinical presentation (Rutherford categories).
b Model 1 þ smoking, hypertension, dyslipidemia, diabetes, CKD.
c Model 2 þ history of CAD, stroke, heart failure, bronchitis, cancer, current treatment.
Table 4. Association between the reduction in hemoglobin (mmol/L) and different outcomes of the study (multivariate analysis) after
exclusion of CI and ALI subjects.
Model 1b Model 2b Model 3c
HR 95% CI HR 95% CI HR 95% CI
Death and amputation
1.21 1.10e1.32 1.17 1.06e1.28 1.14 1.03e1.26
Amputation
1.14 1.04e1.25 1.13 1.02e1.24 1.13 1.03e1.25
a Adjusted for age, gender and PAD clinical presentation (Rutherford categories).
b Model 1 þ smoking, hypertension, dyslipidemia, diabetes, CKD.
c Model 2 þ history of CAD, stroke, heart failure, bronchitis, cancer, current treatment.
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niﬁcant relationship between anemia, its severity, and the
risk of major amputation. This condition may exacerbate
lower limb ischemia. Whether a correction of anemia (e.g.
blood transfusion) could improve the limb and general
prognosis of patients with PAD requires further investiga-
tion. This study presents several limitations. Some patients
(114) were excluded because of a lack of data, but no se-
lection bias is expected. Although the association between
anemia and adverse outcome has been adjusted for several
confounders such as CKD, the cause of anemia for each
patient is not available. Anemia in these patients may be
multifactorial, including iron or vitamin deﬁciency and
inﬂammation, which may have a direct role on limb prog-
nosis. In patients enrolled in this registry after this analysis,
further biological tests are performed to clarify the cause of
anemia. The results will be presented in the future.
CONCLUSIONS
Anemia is common in both male and female patients hos-
pitalized for PAD. This condition is independently associated
with poor outcome both for limbs and generally. The risk of
major amputation and death increases substantially at low
levels of hemoglobin. Whether timely and adequate treat-
ment of anemia in these patients may improve outcome for
limbs and in general is a new ﬁeld for investigation.
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